ArticleFrontiers in immunology2026
Myelin oligodendrocyte glycoprotein antibody-associated disease presenting as encephalitis and concurrent Epstein-Barr virus detection: a case series.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is an autoimmune disorder affecting the central nervous system (CNS), characterized by the presence of autoantibodies against MOG (MOG-IgG) in serum or cerebrospinal fluid (CSF). While Epstein-Barr virus (EBV) is implicated in multiple sclerosis (MS), its role in MOGAD remains unclear. Here, we report five cases of newly diagnosed MOGAD manifesting as encephalitis, in whom concurrent EBV-related laboratory findings were detected. All patients tested positive for serum MOG-IgG by live cell-based assay (CBA). Regarding therapeutic response, three patients exhibited transient improvement in CSF parameters following initial antiviral therapy. However, clinical recovery was observed only after administration of corticosteroids (either high- or low-dose). In refractory cases, additional interventions with intravenous immunoglobulin (IVIG) or tocilizumab were applied. In conclusion, this case series suggests that EBV-associated immune activation may coexist with some MOGAD patients presenting as encephalitis, which requires validation in larger prospective and mechanistic studies in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.